Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:August 11, 2017
End Date:August 31, 2020

Use our guide to learn which trials are right for you!

A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors

This phase I trial studies the side effects and best dose of pembrolizumab and recombinant
interleukin-12 in treating patients with solid tumors. Monoclonal antibodies, such as
pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Recombinant
interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating
white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12
may work better in treating patients with solid tumors.

PRIMARY OBJECTIVES:

I. Establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of
recombinant human interleukin (rhIL)-12 in combination with MK-3475 (pembrolizumab).

SECONDARY OBJECTIVES:

I. Evaluate the safety of the regimen by continuously monitoring adverse events that will be
documented utilizing Common Terminology Criteria for Adverse Events (CTCAE) version (v).5.0.

II. Evaluate the overall response rate (Response Evaluation Criteria in Solid Tumors [RECIST]
v.1.1) and the progression free survival of patients enrolled on the study.

II. Measure CD8+ T cell infiltration by immunohistochemistry in tumor biopsies obtained at
baseline, after one week of rhIL-12 and after 2 cycles of MK-3475 (pembrolizumab) in
combination with rhIL-12.

IV. Conduct exploratory translational laboratory correlative studies utilizing banked
biospecimens (tumor and blood) obtained at baseline and during therapy.

OUTLINE: This is a dose-escalation study of recombinant interleukin-12.

Patients receive recombinant interleukin-12 subcutaneously (SC) on days 2, 5, 9, and 12 and
pembrolizumab intravenously (IV) over 30 minutes on day 8 of course 1 and day 1 of subsequent
courses. Treatment continues for 28 days for course 1 and repeats every 21 days for
subsequent courses for up to 8 courses in the absence of disease progression or unacceptable
toxicity. Patients then receive recombinant interleukin-12 SC on days 2, 5, 9, and 12.
Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up for 3 years.

Inclusion Criteria:

- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard Food and Drug Administration (FDA)-approved
systemic curative or palliative antitumor therapies do not exist or are no longer
effective or for which MK-3475 (pembrolizumab) is FDA-approved as standard of care
therapy

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

- Life expectancy of greater than 12 weeks

- Within 14 days of treatment initiation: Leukocytes >= 2,000/mcL

- Within 14 days of treatment initiation: Absolute neutrophil count >= 1,500/mcL

- Within 14 days of treatment initiation: Platelets >= 100,000/mcL

- Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L

- Within 14 days of treatment initiation: Serum total bilirubin =< upper limit of normal
(ULN) OR direct bilirubin =< ULN for patients with total bilirubin levels > ULN;
(except patients with Gilbert's syndrome, who must have a total bilirubin less than
3.0 mg/dL)

- Within 14 days of treatment initiation: Aspartate aminotransferase (AST) serum
glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum
glutamate pyruvate transaminase (SGPT) =< 2.5 x institutional ULN

- Within 14 days of treatment initiation: Serum creatinine =< 1.5 x ULN OR measured or
calculated creatinine clearance (CrCl) (glomerular filtration rate [GFR] can also be
used in place of creatinine or CrCl) >= 60 mL/min for subject with creatinine levels >
1.5 X institutional ULN

- Within 14 days of treatment initiation: International normalized ratio (INR) or
prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy
as long as (PT) or partial thromboplastin time (PTT) is within therapeutic range of
intended use of anticoagulants

- Within 14 days of treatment initiation: Activated partial thromboplastin time (aPTT)
=< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as prothrombin
time (PT) or partial thromboplastin time (PTT) is within therapeutic range of intended
use of anticoagulants

- Optional tumor biopsies: Patients will be asked permission (consent) to provide tissue
from a recent (within 6 weeks of study entry) archival tissue sample or newly obtained
core or excisional biopsy of a tumor lesion; in addition, for on-study biopsies (after
one week and after 7 weeks of initiating study therapy) and for baseline tumor biopsy
if an archival tissue sample is not available: willingness to undergo biopsies will be
asked; patients who consent to provide tumor biopsies for research should have tumors
deemed relatively safely accessible for biopsies with low likelihood of complication

- Patients must have measurable disease based on RECIST 1.1

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation

- Female patients of childbearing potential should have a negative urine or serum
pregnancy test within 72 hours prior to receiving the first dose of study
medication; if the urine test is positive or cannot be confirmed as negative, a
serum pregnancy test will be required

- Female patients of childbearing potential should be willing to use 2 methods of
birth control or be surgically sterile, or abstain from heterosexual activity for
the course of the study through 120 days after the last dose of study medication;
patients of childbearing potential are those who have not been surgically
sterilized or have not been free from menses for > 1 year

- Should a woman become pregnant or suspect she is pregnant while she is
participating in this study, she should inform her treating physician immediately

- Men treated or enrolled on this protocol must also agree to use adequate
contraception prior to the study, for the duration of study participation, and 4
months after completion of MK-3475 (pembrolizumab) and/or rhIL-12 administration

- Ability to understand and the willingness to sign a written informed consent document

- Patients who are human immunodeficiency virus (HIV) positive may participate IF they
meet the following eligibility requirements:

- They must be stable on their anti-retroviral regimen, and they must be healthy
from an HIV perspective

- They must have an undetectable viral load

- They must have a CD4 count of greater than 250 cells/mcL

- They must not be receiving prophylactic therapy for an opportunistic infection

Exclusion Criteria:

- Patients who have had chemotherapy, targeted small molecule therapy, or radiotherapy
within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
or those who have not recovered from adverse events due to agents administered more
than 4 weeks earlier

- Note: patients with =< grade 2 neuropathy are an exception to this criterion and
may qualify for the study

- Note: if patients received major surgery, they must have recovered adequately
from the toxicity and/or complications from the intervention prior to starting
therapy

- Patients who are currently participating in or have participated in a study of an
investigational agent or using an investigational device within 4 weeks of the first
dose of treatment

- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to the first dose of trial
treatment

- Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not
recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents
administered more than 4 weeks earlier; non-clinically significant adverse events may
be considered as an exception after discussion with and approval by the principal
investigator

- Has a known additional malignancy that is progressing or requires active treatment;
exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
skin, or in situ cervical cancer that has undergone potentially curative therapy

- Patients with known brain active and untreated metastases should be excluded from this
clinical trial

- Patients with carcinomatous meningitis should also be excluded

- Patients with previously treated brain metastases may participate provided they are
stable (without evidence of progression by imaging for at least 4 weeks prior to the
first dose of trial treatment and any neurologic symptoms have returned to baseline),
have no evidence of new or enlarging brain metastases, and are not requiring steroids
for at least 7 days prior to trial treatment

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to MK-3475 (pembrolizumab) and/or rhIL-12 or other agents used in study

- Has an active autoimmune disease requiring systemic treatment within the past 3 months
or a documented history of clinically severe autoimmune disease, or a syndrome that
requires systemic steroids or immunosuppressive agents; patients with vitiligo or
resolved childhood asthma/atopy would be an exception to this rule; patients that
require intermittent use of bronchodilators or local steroid injections would not be
excluded from the study; patients with hypothyroidism stable on hormone replacement or
Sjogren's syndrome will not be excluded from the study

- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the patient's
participation for the full duration of the trial, or is not in the best interest of
the patient to participate, in the opinion of the treating investigator

- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial

- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically
targeting T-cell co-stimulation or checkpoint pathways)

- Patients on any systemic corticosteroid therapy within one week before the planned
date for first dose on study would not be eligible; exception: patients on physiologic
replacement doses of corticosteroids are permitted

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, interstitial lung disease or active, non-infectious pneumonitis,
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
requirements

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment; pregnant women are excluded;
breastfeeding should be discontinued if the mother is treated MK-3475

- Men and non-pregnant, non-breast-feeding women may be enrolled if they are willing to
use 2 methods of birth control or are considered highly unlikely to conceive; highly
unlikely to conceive is defined as 1) surgically sterilized, or 2) postmenopausal (a
woman who is >= 45 years of age and has not had menses for greater than 2 years will
be considered postmenopausal), or 3) not heterosexually active for the duration of the
study; the two birth control methods can be barrier method or a barrier method plus a
hormonal method to prevent pregnancy; patients should start using birth control from
study visit 1 throughout the study period up to 120 days after the last dose of study
therapy; the following are considered adequate barrier methods of contraception:
diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide;
appropriate hormonal contraceptives will include any registered and marketed
contraceptive agent that contains an estrogen and/or a progestational agent (including
oral, subcutaneous, intrauterine, or intramuscular agents)

- Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
detected)

- Has received a live vaccine within 30 days prior to the first dose of trial treatment

- Patient would not be eligible if he/she has known psychiatric or substance abuse
disorders that would interfere with cooperation with the requirements of the trial
We found this trial at
24
sites
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Dale R. Shepard
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Geoffrey I. Shapiro
Phone: 888-823-5923
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Geoffrey I. Shapiro
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Sarah W. Gordon
Phone: 888-823-5923
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Bradley R. Corr
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Nilofer S. Azad
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Geoffrey I. Shapiro
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Geoffrey I. Shapiro
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Carrie Lee
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Principal Investigator: Andrea Wang-Gillam
Phone: 800-600-3606
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: James L. Abbruzzese
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: Thomas J. George
Phone: 352-273-8010
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Mohammed M. Milhem
Phone: 800-237-1225
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Mina Nikanjam
Phone: 858-822-5354
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Roman Groisberg
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Haven, Connecticut 06510
Principal Investigator: Navid Hafez
Phone: 203-785-5702
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Navid Hafez
Phone: 203-785-5702
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: James J. Lee
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Jonathan W. Riess
Phone: 916-734-3089
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63129
Principal Investigator: Andrea Wang-Gillam
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Andrea Wang-Gillam
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
11155 Dunn Road
Saint Louis, Missouri 63136
Principal Investigator: Andrea Wang-Gillam
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
150 Entranceway Drive
Saint Peters, Missouri 63376
Principal Investigator: Andrea Wang-Gillam
Phone: 800-600-3606
?
mi
from
Saint Peters, MO
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Pamela N. Munster
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials